Should I buy or sell IDEXX Laboratories stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares. View IDXX analyst ratings or view top-rated stocks .

What is IDEXX Laboratories' stock price target for 2024?

9 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' shares. Their IDXX share price targets range from $460.00 to $655.00. On average, they predict the company's stock price to reach $591.50 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price. View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts .

How have IDXX shares performed in 2024?

IDEXX Laboratories' stock was trading at $555.05 on January 1st, 2024. Since then, IDXX shares have decreased by 14.1% and is now trading at $476.95. View the best growth stocks for 2024 here .

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our IDXX earnings forecast .

How can I listen to IDEXX Laboratories' earnings call?

IDEXX Laboratories will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Monday, February, 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. The business earned $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a trailing twelve-month return on equity of 71.66%. The firm's revenue was up 8.8% on a year-over-year basis. During the same period last year, the company earned $2.05 EPS. Read the conference call transcript .

What ETFs hold IDEXX Laboratories' stock?

ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ) , Sterling Capital Focus Equity ETF (LCG) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , First Trust Water ETF (FIW) , iShares U.S. Medical Devices ETF (IHI) , Neuberger Berman Disrupters ETF (NBDS) , Putnam Sustainable Future ETF (PFUT) and Nuveen Winslow Large-Cap Growth ESG ETF (NWLG) .

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories updated its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share guidance of 10.840-11.330 for the period, compared to the consensus estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com . Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA) , Netflix (NFLX) , PayPal (PYPL) , Mastercard (MA) , Adobe (ADBE) , Tesla (TSLA) , Alibaba Group (BABA) , Block (SQ) , Walt Disney (DIS) and Shopify (SHOP) .

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Westwind Capital (0.05%), Bourne Lent Asset Management Inc. (0.05%), Franklin Street Advisors Inc. NC (0.05%), Woodstock Corp (0.03%), Bath Savings Trust Co (0.03%) and Czech National Bank (0.02%). Insiders that own company stock include Brian P Mckeon , Daniel M Junius , George Fennell , Giovani Twigge , James F Polewaczyk, James F Polewaczyk , Jonathan Jay Mazelsky , Jonathan W Ayers , Kathy V Turner , Kathy V Turner , M Anne Szostak , Michael Lane , Nimrata Hunt and Sophie V Vandebroek . View institutional ownership trends .

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free IDXX Stock Alerts

$477.79

-0.45 (-0.09%)

(As of 04:23 PM ET)

Compare

Today's Range: $475.73
▼
$483.10
50-Day Range: $478.24
▼
$576.87
52-Week Range: $372.50
▼
$583.39

Volume: 396,748 shs
Average Volume: 427,323 shs
Market Capitalization: $39.68 billion

P/E Ratio: 47.45
Dividend Yield: N/A
Price Target: $591.50

Get IDEXX Laboratories alerts:

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 24.0% Upside
$591.50 Price Target
Short Interest: Healthy
2.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.09
Upright™ Environmental Score
News Sentiment: 1.13
Based on 6 Articles This Week
Insider Trading: Selling Shares
$24.87 M Sold Last Quarter
Proj. Earnings Growth: 14.53%
From $11.15 to $12.77 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.20 out of 5 stars

Medical Sector

147th out of 914 stocks

Diagnostic Substances Industry

3rd out of 10 stocks

2.3

Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.14% of the float of IDEXX Laboratories has been sold short.
Short Interest Ratio / Days to Cover
IDEXX Laboratories has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in IDEXX Laboratories has recently decreased by 2.22%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEXX Laboratories has received a 46.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Urine analyzers", "Biochemical assay kits", and "Veterinary laboratories for pets" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEXX Laboratories is -2.09.

2.8

News and Social Media Coverage

News Sentiment
IDEXX Laboratories has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for IDEXX Laboratories this week, compared to 8 articles on an average week.
Search Interest
7 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,871,960.00 in company stock.
Percentage Held by Insiders
Only 2.11% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 14.53% in the coming year, from $11.15 to $12.77 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 47.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.69.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 47.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 206.33.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 3.77. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 26.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IDXX Stock News Headlines

April 18, 2024 | nasdaq.com

Commit To Buy Idexx Laboratories At $320, Earn 1.4% Annualized Using Options

April 18, 2024 | americanbankingnews.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Brokerages

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - IDXX

April 12, 2024 | investorplace.com

New AI Bot Predicts These 7 Stocks Will Mint Millionaires

April 10, 2024 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Given Outperform Rating at William Blair

April 8, 2024 | seekingalpha.com

IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)

April 4, 2024 | businesswire.com

IDEXX Laboratories to Release 2024 First Quarter Financial Results

April 18, 2024 | Crypto 101 Media (Ad)

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

April 3, 2024 | finance.yahoo.com

IDEXX Laboratories, Inc.: Idexx's Upcoming New InVue Platform Launch Should Support Growth Into the Long Term

March 29, 2024 | finance.yahoo.com

IDEXX Laboratories (IDXX) Gained 27% on Improved Operating Margins

March 21, 2024 | finance.yahoo.com

Strong Fiscal Q3 Earnings Pushed IDEXX Laboratories (IDXX) in Q4

March 19, 2024 | finance.yahoo.com

IDEXX Laboratories' (NASDAQ:IDXX) earnings growth rate lags the 19% CAGR delivered to shareholders

March 16, 2024 | ca.finance.yahoo.com

IDXX Oct 2024 780.000 call

March 16, 2024 | finance.yahoo.com

IDXX Apr 2024 280.000 put

March 12, 2024 | finance.yahoo.com

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

March 8, 2024 | finance.yahoo.com

Executive Vice President James Polewaczyk Sells Shares of IDEXX Laboratories Inc (IDXX)

February 27, 2024 | benzinga.com

Here's How Much $1000 Invested In IDEXX Laboratories 15 Years Ago Would Be Worth Today

February 24, 2024 | msn.com

IDEXX Laboratories (IDXX) Price Target Increased by 5.82% to 616.21

February 23, 2024 | finance.yahoo.com

IDXX Jun 2024 640.000 call

February 22, 2024 | finance.yahoo.com

IDEXX Laboratories (IDXX) Rebounded After Significant Drawdown From July Highs

February 22, 2024 | benzinga.com

IDEXX Laboratories Stock (NASDAQ:IDXX), Analyst Ratings, Price Targets, Predictions

February 21, 2024 | benzinga.com

IDEXX Laboratories Stock (NASDAQ:IDXX) Earnings Dates and Earning Calls

February 20, 2024 | finance.yahoo.com

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

February 20, 2024 | businesswire.com

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

February 15, 2024 | ca.finance.yahoo.com

IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

February 15, 2024 | prnewswire.com

IDEXX Launches Vello™, an Innovative Pet Owner Engagement Software Solution, Streamlining How Practices and Clients Connect

See More Headlines

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/05/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:IDXX
CUSIP: 45168D10
CIK: 874716
Web: www.idexx.com
Phone: (207) 556-0300
Fax: 207-556-4346
Employees: 11,000
Year Founded: 1983

Price Target and Rating

Average Stock Price Target: $591.50
High Stock Price Target: $655.00
Low Stock Price Target: $460.00
Potential Upside/Downside: +23.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $10.07
Trailing P/E Ratio: 47.60
Forward P/E Ratio: 42.99
P/E Growth: 3.77
Net Income: $845.04 million
Net Margins: 23.08%
Pretax Margin: 28.99%
Return on Equity: 71.66%
Return on Assets: 28.11%

Debt

Debt-to-Equity Ratio: 0.42
Current Ratio: 1.57
Quick Ratio: 1.17

Sales & Book Value

Annual Sales: $3.66 billion
Price / Sales: 10.87
Cash Flow: $11.32 per share
Price / Cash Flow: 42.36
Book Value: $17.88 per share
Price / Book: 26.81

Miscellaneous

Outstanding Shares: 83,050,000
Free Float: 81,302,000
Market Cap: $39.81 billion
Optionable: Optionable
Beta: 1.26

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Jonathan J. Mazelsky (Age 63)
President, CEO & Director
Comp: $2.04M
Mr. Brian P. McKeon (Age 62)
CFO, Executive VP & Treasurer
Comp: $1.06M
Mr. James F. Polewaczyk (Age 60)
Executive VP & Chief Commercial Officer
Comp: $889.99k
Mr. John Hart
Senior Vice President of Global Operations
Mr. Jeffery D. Chadbourne (Age 48)
Senior Vice President of Commercial Finance & Sales Operations
Mr. Ken Grady
Senior VP & Chief Information Officer
Ms. Sharon E. Underberg (Age 63)
Executive VP, General Counsel, & Corporate Secretary
Comp: $881.05k
Mr. Michael P. Johnson (Age 46)
Executive VP & Chief Human Resources Officer
Mr. George J. Fennell (Age 55)
Senior VP & Chief Revenue Officer
Ms. Kerry Bennett
Senior VP and GM of Product & Strategy of Global Reference Labs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

Recent increase in institutional holdings by key investors indicates confidence in the company's future growth prospects.
IDEXX Laboratories operates in multiple segments including Companion Animal Group, Water Quality Products, and Livestock, Poultry and Dairy, diversifying its revenue streams.
The company offers a wide range of diagnostic products and services for veterinary, livestock, and water testing markets, catering to diverse customer needs.
Strong market presence in various regions globally, providing opportunities for continued expansion and revenue growth.
Current stock price is relatively stable and has shown positive momentum in recent periods, presenting a potential investment opportunity.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

Market competition in the diagnostic substances industry may impact IDEXX Laboratories' market share and pricing power.
Regulatory changes or challenges in different regions could affect the company's operations and profitability.
Economic downturns or global health crises may impact demand for veterinary and diagnostic products, affecting the company's financial performance.
Dependency on key markets like companion animal veterinary and livestock sectors for a significant portion of revenue, exposing the company to sector-specific risks.
Fluctuations in raw material costs or supply chain disruptions could impact IDEXX Laboratories' production costs and margins.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.
What is IDEXX Laboratories' stock price target for 2024?: 9 equities research analysts have issued 12-month price objectives for IDEXX Laboratories' shares. Their IDXX share price targets range from $460.00 to $655.00. On average, they predict the company's stock price to reach $591.50 in the next twelve months. This suggests a possible upside of 24.0% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.
How have IDXX shares performed in 2024?: IDEXX Laboratories' stock was trading at $555.05 on January 1st, 2024. Since then, IDXX shares have decreased by 14.1% and is now trading at $476.95.
View the best growth stocks for 2024 here.
When is IDEXX Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our IDXX earnings forecast.
How can I listen to IDEXX Laboratories' earnings call?: IDEXX Laboratories will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were IDEXX Laboratories' earnings last quarter?: IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its quarterly earnings data on Monday, February, 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. The business earned $901.60 million during the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a trailing twelve-month return on equity of 71.66%. The firm's revenue was up 8.8% on a year-over-year basis. During the same period last year, the company earned $2.05 EPS.
Read the conference call transcript.

What ETFs hold IDEXX Laboratories' stock?: ETFs with the largest weight of IDEXX Laboratories (NASDAQ:IDXX) stock in their portfolio include ProShares Pet Care ETF (PAWZ), Sterling Capital Focus Equity ETF (LCG), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), First Trust Water ETF (FIW), iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Putnam Sustainable Future ETF (PFUT) and Nuveen Winslow Large-Cap Growth ESG ETF (NWLG).
What guidance has IDEXX Laboratories issued on next quarter's earnings?: IDEXX Laboratories updated its FY 2024 earnings guidance on Monday, February, 5th. The company provided earnings per share guidance of 10.840-11.330 for the period, compared to the consensus estimate of 11.000. The company issued revenue guidance of $3.9 billion-$4.0 billion, compared to the consensus revenue estimate of $4.0 billion.
What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?: 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.
What other stocks do shareholders of IDEXX Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).
Who are IDEXX Laboratories' major shareholders?: IDEXX Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Westwind Capital (0.05%), Bourne Lent Asset Management Inc. (0.05%), Franklin Street Advisors Inc. NC (0.05%), Woodstock Corp (0.03%), Bath Savings Trust Co (0.03%) and Czech National Bank (0.02%). Insiders that own company stock include Brian P Mckeon, Daniel M Junius, George Fennell, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt and Sophie V Vandebroek.
View institutional ownership trends.
How do I buy shares of IDEXX Laboratories?: Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial